Effects of Celecoxib After Percutaneous Coronary Intervention
Overview
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.
Full Title of Study: “Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: October 2008
Interventions
- Drug: Celecoxib
- celecoxib: loading and maintenance for 6 months
Arms, Groups and Cohorts
- No Intervention: Control
- Active Comparator: Celecoxib
Clinical Trial Outcome Measures
Primary Measures
- Late luminal loss at 6 months
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography Exclusion Criteria:
- Acute ST elevation MI – Left main disease – Contraindications to aspirin, clopidogrel or celecoxib – Severe congestive heart failure – Expected survival < 2 years – Hepatic dysfunction – Currently taking NSAIDs or any COX-2 inhibitor – Renal dysfunction – Use of warfarin
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Seoul National University Hospital
- Provider of Information About this Clinical Study
- Seoul national university hostpial, Seoul National University Hospital
- Overall Official(s)
- Bon-Kwon Koo, MD, PhD, Principal Investigator, Seoul National University Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.